Two independent studies by Al-Ejeh et al. and Ortiz-Ruiz et al. published in Oncotarget last year concluded that ERK5 is an attractive target in triple negative breast cancer. This evidence concerns the gene MAPK7 and triple-negative breast carcinoma.